fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Judge’s Ruling Clears The Way For UnitedHealth’s Acquisition Of Change Healthcare – $UNH $DIA $INVO

By John F. Heerdink, Jr.

According to recent reports, the U.S. Justice Department has decided to drop its appeal against UnitedHealth Group’s (UNH) acquisition of Change Healthcare for almost $8 billion in 2022. Initially, the Justice Department had argued that UnitedHealth, the largest health insurer in the U.S., would gain access to its competitors’ data and lead to higher healthcare costs. UnitedHealth countered by stating that the acquisition would simplify payment and administrative procedures.

The Justice Department’s attempt to block the acquisition was denied by a U.S. judge in September, despite its lawsuit last February. As a result, the all-cash deal was completed in October. The department appealed the decision to the U.S. Court of Appeals in the District of Columbia, but has now withdrawn the appeal.


Dow 30 component UnitedHealth Group Incorporated (UNH) operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, individuals, and military service members; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services. To learn more about (UNH) please visit the Vista Partners Company Dedicated UNH Coverage Page


Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.



DID YOU KNOW?…

 
On Monday, March 20, INVO Bioscience (NASDAQ: INVO) announced that it has signed binding agreements to acquire a materially transformative acquisition of the Wisconsin Fertility Institute. The Madison-based fertility center primarily offers conventional IVF procedures and generated approximately $5.5 million in revenue and net income of approximately $1.9 million for the trailing 12-month period ended September 30, 2022.
 
 
 
Wisconsin Fertility Institute is led by internationally renowned and well-respected fertility expert, Dr. Elizabeth Pritts, who will continue to serve as the clinic’s lead physician for a minimum period of three years from the closing of the acquisition. Dual-certified in General Obstetrics and Gynecology, as well as Reproductive Endocrinology and Infertility, Dr. Pritts completed a surgical fellowship in Advanced Gynecologic Laparoscopy and Hysteroscopy. She is also a national leader in the use of robotic surgery for gynecologic disorders. Dr. Pritts served as an assistant professor in reproductive endocrinology and infertility at the University of Wisconsin Medical School, as a clinical fellow at the University of California at San Francisco, and as an instructor at Yale University School of Medicine. She has authored more than 70 articles for scientific publications and has lectured throughout the world on reproduction and fertility.
 
 

Dr. Elizabeth Pritts, M.D., Wisconsin Fertility Institute’s Co-founder

 
 
“I’m excited to be teaming up with INVO as a unique and attractive partner to help advance us to the next phase of our practice. INVO’s commercial strategy and patient focus, along with its public-company platform and the INVOcell technology itself, offers an exciting pathway to build value and increase access to an efficient, effective, affordable, and connected experience in reproductive treatment. Our team looks forward to being an integral part of INVO’s long-term growth and success.” Dr. Elizabeth Pritts, Wisconsin Fertility Institute’s co-founder.
 
 
 
Wisconsin Fertility Institute joins INVO’s expanding list of fertility clinics, including operating clinics in Atlanta (Bloom Fertility), Birmingham (Innovative Fertility Specialists) and Monterrey, Mexico (Positib Fertility), as well as future clinics under development, such as the wholly owned INVO Center in Tampa, Florida that is currently under construction. INVO’s revolutionary medical device, the INVOcell, allows fertilization and early embryo development to occur in vivo with the woman’s body and is also available at a growing list of non-affiliated fertility centers in the United States and around the world.
 
(Read Original Story: US drops appeal of UnitedHealth acquisition of Change Healthcare in Reuters)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us